Big pharma, CRCs can work together: AstraZeneca czar
29 April, 2004 by Melissa TrudingerThe thing AstraZeneca finds hardest about its relationship with the Cooperative Research Centre for Chronic Inflammatory Diseases is coping with incompatible timezones.
Austin spin-off XenoTrans earns Geron backing
28 April, 2004 by Melissa TrudingerUS biotechnology company Geron has taken a 25 per cent equity position in Austin Research Institute spin-off XenoTrans, in return for granting the company a non-exclusive licence to use Geron's nuclear transfer technology to produce transgenic pigs for xenotransplantation, and a share in future revenues.
Virax begins prostate cancer vaccine trial
28 April, 2004 by Graeme O'NeillMelbourne immunotherapy developer Virax Holdings (ASX:VHL) has begun a pre-clinical trial of its novel candidate vaccine for late-stage prostate cancer at the Royal Adelaide Hospital Cancer Centre.
GroPep posts fourth consecutive positive quarter
28 April, 2004 by Graeme O'NeillAdelaide biopharma GroPep (ASX:GRO) today announced its fourth consecutive quarter of positive operating and net cash flow.
CSIRO, Bayer in RNAi deal
27 April, 2004 by Graeme O'NeillInternational agbiotech company Bayer CropScience has acquired a licence from CSIRO to develop new crops using the patented RNA interference (RNAi) gene-silencing technology developed by CSIRO Plant Industry researchers.
AGT pipeline boosted in merger with US firm
27 April, 2004 by Melissa TrudingerAGT Biosciences (ASX:AGT) has merged with US company ChemGenex Therapeutics to create a genomics-driven pharmaceutical company with two products in Phase II clinical trials.
Obesity drug alters brain, says scientist
23 April, 2004 by Staff WritersA British scientist has warned that Sanofi-Synthelabo's experimental obesity drug Acomplia could alter the way people think.
Queensland's Xenome files IND for painkiller
22 April, 2004 by Renate KrelleXenome -- 25 per cent owned by Medica Holdings (ASX:MCA) -- has filed an investigational new drug (IND) application with the US Food and Drug Administration for its Xen2174 cancer painkiller, which is derived from cone shell venom.
Biotechs, big pharma benefit as first P3 grants awarded
22 April, 2004 by Renate KrelleThe federal government has today ladled out just under 60 per cent of the funding for its five-year $150 million Pharmaceutical Partnerships Program -- known as P3 -- giving 11 pharmaceutical and biotech companies a cash boost to fund drug development.
Pharmaxis says study points to larger market for lung drug
21 April, 2004 by Renate KrelleSydney-based Pharmaxis (ASX:PXS) believes the market for its Aridol lung function test has the potential to double, after a pilot Swiss study gave Aridol the stamp of approval for predicting patients' response to steroids used to treat chronic obstructive pulmonary disease.
Proteome Systems to assist in Huntington's research
20 April, 2004 by Graeme O'NeillA US foundation that sponsors research into Huntington's disease has turned to Sydney proteomics company Proteome Systems to search for prognostic markers and targets for drugs to treat the fatal neurodegenerative disorder.
Meditech says Phase II trial shows early promise
20 April, 2004 by Renate KrelleMeditech (ASX:MTR) will enrol an additional 12 patients in its Phase II trial, following promising early results from its HyCAMP treatment for advanced colorectal cancer patients at the Royal Melbourne Hospital.
Prima encouraged by Biomira result
16 April, 2004 by Melissa TrudingerPrima Biomed (ASX:PRR) has been cheered by clinical trial results from commercial partner Biomira.
By the pricking of my thumbs: shark and crustacean extracts may fight osteoarthritis
15 April, 2004 by Graeme O'NeillCan an extract of shark cartilage and crustacean shells alleviate the pain and inflammation of symptoms of osteoarthritis, the most common disease of aging?
pSivida raises $21 million as clinical trials approach
15 April, 2004 by Melissa TrudingerPerth-based nanotechnology company pSivida (ASX: PSD) has raised $21 million in an international placement - enough cash to see the company through to 2006, when it expects its first revenues.
